CEACAM1 Alternative Splicing in Liver Ischemia-Reperfusion Injury
CEACAM1 选择性剪接在肝脏缺血再灌注损伤中的作用
基本信息
- 批准号:10622462
- 负责人:
- 金额:$ 54.09万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-08-01 至 2027-07-31
- 项目状态:未结题
- 来源:
- 关键词:AccelerationAcuteAddressAdvocateAlternative SplicingAnti-Inflammatory AgentsAutophagocytosisBiological MarkersBiometryBiopsyBrain DeathCardiac DeathCell Culture SystemCell DeathCellsClinicalComplementComplement component C1CryopreservationCytoplasmCytoprotectionDataExclusionExonsGenesHepaticHepatic TissueHepatocyteHumanImmuneImpairmentInfiltrationInflammationInjuryInterventionIschemiaLifeLiverLymphocyteMAP Kinase GeneMacrophageMediatingMessenger RNAMucosal ImmunityMusMyelogenousNatural ImmunityNatural regenerationOperative Surgical ProceduresOrganOrgan DonorOrgan PreservationOrgan TransplantationOutcomePathway interactionsPatientsPhasePhenotypeProtein IsoformsRNA SplicingRecoveryRegulationRejuvenationReperfusion InjuryReportingResistanceResolutionSentinelSignal TransductionSterilityStressTissuesTransgenic MiceTransplantationTransplantation SurgeryVariantWaiting ListsWarm Ischemiacarcinoembryonic antigen-related cell adhesion moleculesclinically relevantend stage liver diseaseexperimental studyfunctional improvementimmunoregulationimprovedinsightliver functionliver inflammationliver ischemialiver transplantationmortalitymouse modelneutrophilnovelnovel therapeuticsp38 Mitogen Activated Protein Kinasepreservationpreventprogramsregenerativerepairedscreeningstandard of caresuccesssynergismtransplant model
项目摘要
PROJECT 1 – SUMMARY/ABSTRACT
Project 1 competitive renewal addresses the unmet clinical and scientific needs to enhance donor liver supply
through organ “rejuvenation.” We reported that hepatic CEACAM1 (encoded by CC1 gene; CD66a) dictates
donor liver quality, and prevents early OLT injury in mice and humans. CC1 mRNA undergoes alternative splicing
(AS) to generate splice variants, characterized by the inclusion (CC1-L; long) or exclusion (CC1-S; short) of exon
7. Hypothesis: Hepatocyte CC1-S functions as a cytoprotective sentinel, while CC1-L in OLT-infiltrating recipient-
derived neutrophils, regulates liver IR-inflammation and fine-tunes its resolution.
Aim 1: Delineate mechanisms by which hepatic CC1-S isoform promotes cellular protection in IR-
stressed mouse OLT. Hypothesis: Antisense oligomer morpholinos (MOs)-enforced AS of hepatic CC1
generates CC1-S isoform in the donor mouse liver, which under the control of HIF-1α, stimulates cytoprotection
by blocking p-p38 (under cold IR-stress) while promoting GPX4 and targeting ferroptosis (under warm IR-stress).
Here, we will ascertain whether 1.1: CC1-AS accelerates otherwise impaired hepatic recovery in the acute and
the resolution phase of IR-inflammation. 1.2: CC1-S controls IRI-OLT by regulating hepatic cell death pathways.
1.3: CC1-S-mediated cytoprotection is controlled by HIF-1α signaling under warm vs. cold hepatic IR-stress.
Aim 2: Define mechanisms by which neutrophil CC1-L isoform exerts anti-inflammatory and
cytoprotective functions in IR-stressed mouse OLT. Hypothesis: Recipient CC1-L neutrophils counteract acute
IRI-OLT, and stimulate inflammation resolution by orchestrating N1/N2 polarization, with resultant liver
homeostatic/regenerative remodeling. We will study whether 2.1: Recipient CC1-L deficient immune cells
exacerbate hepatic IRI-OLT. 2.2: CC1-L polarizes N2 neutrophils to promote an anti-inflammatory phenotype/
improve OLT outcomes. 2.3: CC1-L proficient neutrophils polarize M2 macrophages/promote hepatic autophagy.
Aim 3: Elucidate mechanisms by which hepatic CC1-S isoform rejuvenates discarded human livers
subjected to normothermic machine preservation (NMP). Hypothesis: NMP, supplemented with HIF-1α – CC1-
S axis modifiers, improves the function of discarded human livers by mitigating ferroptosis while promoting
autophagy. We will incorporate the emerging NMP strategy with adjunctive CC1-intervention to assess whether
3.1: MOs-conditioned humanized CC1 transgenic mice (huCC1-Tg) mimic the effects of CC1-AS upon liver IR-
stress in normal mice but be translatable to the human liver. 3.2: CC1-S isoform synergizes with HIF-1α to
improve liver function. 3.3: CC1-S synergizes with HIF-1α to enhance cytoprotection in human livers.
Integration with PPG: Project 1 complements studies assessing homeostatic mechanisms in the
resolution of IRI-OLT in Project 2. Aim 1-2 in Project 1 will be validated by the screening of human OLT biopsies
to accelerate assessments of clinical innate immune phenotypes in Project 3. Project 1 is dependent on Core A
(Administrative), Core B (Mouse and Human OLT Surgery), and Core C (Computational and Biostatistics).
项目1--摘要/摘要
项目1竞争性更新解决了未得到满足的临床和科学需求,以增加供体肝脏的供应
通过器官“返老还童”。我们报道了肝脏CEACAM1(由CC1基因编码;CD66a)决定了
供体肝脏质量,并防止小鼠和人类的早期原位肝移植损伤。CC1基因经历选择性剪接
(AS)产生剪接变体,特征是外显子的包含(CC1-L;长)或排除(CC1-S;短)
7.假设:肝细胞CC1-S起细胞保护作用,而CC1-L在原位肝移植浸润性受体中起细胞保护作用。
衍生的中性粒细胞,调节肝脏IR炎症并微调其分辨率。
目的1:探讨肝脏CC1-S亚型促进细胞保护的机制。
应激小鼠原位肝移植。假设:反义寡聚吗啡(MOS)--作为肝脏CC1的增强因子
在供体小鼠肝脏中产生CC1-S亚型,在HIF-1α的控制下,刺激细胞保护
通过阻断p-p38(在冷IR应激下),同时促进Gpx4和靶向铁下垂(在热IR应激下)。
在这里,我们将确定1.1:CC1-AS是否加速了急性和慢性肝炎患者原本受损的肝脏恢复。
IR炎症消退阶段。CC1-S通过调节肝细胞死亡途径控制IRI-OLT。
CC1-S介导的细胞保护作用受HIF-1α信号调控。
目的2:明确中性粒细胞CC1-L异构体抗炎作用的机制。
IR应激小鼠原位肝移植的细胞保护作用。假设:受体CC1-L中性粒细胞中和急性
IRI-OLT,并通过协调N1/N2极化刺激炎症消退,并产生肝脏
动态平衡/再生重塑。我们将研究2.1:受体CC1-L是否存在免疫细胞缺陷
加重肝脏IRI-OLT。2.2:CC1-L极化中性粒细胞促进抗炎表型/
改善OLT结果。L熟练的中性粒细胞极化M2巨噬细胞/促进肝脏自噬。
目的3:阐明肝CC1-S亚型使废弃的人肝脏恢复活力的机制
进行常温机器保存(NMP)。假设:NMP,补充HIF-1α-CC1-
S轴修饰剂,通过在促进的同时缓解铁下垂来改善废弃人体肝脏的功能
自噬。我们将把新兴的国家管理计划战略与辅助的CC1干预结合起来,以评估
3.1:MOS条件化人源化CC1转基因小鼠(huCC1-TG)模拟CC1-AS对肝脏IR的影响
应激在正常小鼠,但可翻译到人的肝脏。CC1-S亚型与HIF-1α协同作用
改善肝功能。3.3CC1-S与HIF-1α协同作用增强人肝脏细胞保护作用。
与PPG的整合:项目1补充了评估体内平衡机制的研究
项目2中IRI-OLT的解析。项目1中的目标1-2将通过对人类OLT活检的筛选来验证
在项目3中加速临床天然免疫表型的评估。项目1依赖于核心A
(行政)、核心B(老鼠和人类原位移植手术)和核心C(计算和生物统计学)。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jerzy W Kupiec-Weglinski其他文献
Jerzy W Kupiec-Weglinski的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jerzy W Kupiec-Weglinski', 18)}}的其他基金
THE RELAXIN RECEPTOR GR/RXFP1 SIGNALING IN LIVER TRANSPLANT ISCHEMIA-REPERFUSION INJURY AND THE INFLAMMATION RESOLUTION
松弛素受体 GR/RXFP1 信号在肝移植缺血再灌注损伤和炎症消退中的作用
- 批准号:
10101174 - 财政年份:2020
- 资助金额:
$ 54.09万 - 项目类别:
THE RELAXIN RECEPTOR GR/RXFP1 SIGNALING IN LIVER TRANSPLANT ISCHEMIA-REPERFUSION INJURY AND THE INFLAMMATION RESOLUTION
松弛素受体 GR/RXFP1 信号在肝移植缺血再灌注损伤和炎症消退中的作用
- 批准号:
10685284 - 财政年份:2020
- 资助金额:
$ 54.09万 - 项目类别:
THE RELAXIN RECEPTOR GR/RXFP1 SIGNALING IN LIVER TRANSPLANT ISCHEMIA-REPERFUSION INJURY AND THE INFLAMMATION RESOLUTION
松弛素受体 GR/RXFP1 信号在肝移植缺血再灌注损伤和炎症消退中的作用
- 批准号:
10472636 - 财政年份:2020
- 资助金额:
$ 54.09万 - 项目类别:
THE RELAXIN RECEPTOR GR/RXFP1 SIGNALING IN LIVER TRANSPLANT ISCHEMIA-REPERFUSION INJURY AND THE INFLAMMATION RESOLUTION
松弛素受体 GR/RXFP1 信号在肝移植缺血再灌注损伤和炎症消退中的作用
- 批准号:
10268216 - 财政年份:2020
- 资助金额:
$ 54.09万 - 项目类别:
Innate-Adaptive Immune Interface in Liver Ischemia-Reperfusion Injury
肝脏缺血再灌注损伤中的先天适应性免疫界面
- 批准号:
9975698 - 财政年份:2017
- 资助金额:
$ 54.09万 - 项目类别:
Innate-Adaptive Immunoregulation in Liver Transplant Ischemia/Reperfusion Injury
肝移植缺血/再灌注损伤中的先天适应性免疫调节
- 批准号:
9359428 - 财政年份:2017
- 资助金额:
$ 54.09万 - 项目类别:
Innate-Adaptive Immunoregulation in Liver Transplant Ischemia/Reperfusion Injury
肝移植缺血/再灌注损伤中的先天适应性免疫调节
- 批准号:
9975685 - 财政年份:2017
- 资助金额:
$ 54.09万 - 项目类别:
Innate-Adaptive Immunoregulation in Liver Transplant Ischemia/Reperfusion Injury
肝移植缺血/再灌注损伤中的先天适应性免疫调节
- 批准号:
9750602 - 财政年份:2017
- 资助金额:
$ 54.09万 - 项目类别:
相似海外基金
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 54.09万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 54.09万 - 项目类别:
Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 54.09万 - 项目类别:
Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 54.09万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 54.09万 - 项目类别:
Standard Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 54.09万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 54.09万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 54.09万 - 项目类别:
Research Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 54.09万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
- 批准号:
484000 - 财政年份:2023
- 资助金额:
$ 54.09万 - 项目类别:
Operating Grants














{{item.name}}会员




